Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02230228
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:52.004754+00:00
Published At
2025-04-27T00:00:00+00:00
Record Updated At
2025-04-27
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Stargardt Disease", "Age-related Macular Degeneration", "Other Retinal Dystrophies"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-04-27"
protocolSection.identificationModule.nctId
"NCT02230228"
protocolSection.identificationModule.officialTitle
"A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Stargardt Disease (protocolSection.conditionsModule.conditions)
  • Age-related Macular Degeneration (protocolSection.conditionsModule.conditions)
  • Other Retinal Dystrophies (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.